| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatoblastoma | 26 | 2025 | 186 | 5.470 |
Why?
|
| Liver Neoplasms | 36 | 2025 | 1351 | 4.820 |
Why?
|
| Oncogene Proteins, Fusion | 27 | 2025 | 219 | 3.370 |
Why?
|
| Carcinoma, Hepatocellular | 15 | 2025 | 968 | 2.510 |
Why?
|
| Translocation, Genetic | 21 | 2025 | 348 | 2.140 |
Why?
|
| Dermatofibrosarcoma | 9 | 2018 | 16 | 2.130 |
Why?
|
| Gene Rearrangement | 15 | 2014 | 321 | 2.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 23 | 2015 | 1222 | 1.820 |
Why?
|
| In Situ Hybridization, Fluorescence | 28 | 2016 | 748 | 1.760 |
Why?
|
| Biomarkers, Tumor | 22 | 2024 | 1559 | 1.760 |
Why?
|
| Soft Tissue Neoplasms | 9 | 2014 | 128 | 1.730 |
Why?
|
| Gene Fusion | 6 | 2024 | 59 | 1.610 |
Why?
|
| Skin Neoplasms | 10 | 2020 | 880 | 1.220 |
Why?
|
| Child | 75 | 2025 | 25081 | 1.200 |
Why?
|
| Calmodulin-Binding Proteins | 6 | 2014 | 63 | 1.130 |
Why?
|
| Immunohistochemistry | 22 | 2017 | 1597 | 1.040 |
Why?
|
| Sarcoma, Ewing | 7 | 2013 | 111 | 1.010 |
Why?
|
| Humans | 142 | 2025 | 126673 | 0.940 |
Why?
|
| Neoplasms | 8 | 2025 | 2852 | 0.940 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2018 | 43 | 0.920 |
Why?
|
| RNA-Binding Proteins | 8 | 2014 | 533 | 0.910 |
Why?
|
| Transcription Factors | 14 | 2022 | 2337 | 0.890 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2024 | 10 | 0.870 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2025 | 77 | 0.850 |
Why?
|
| Sarcoma | 6 | 2025 | 205 | 0.850 |
Why?
|
| Mutation | 13 | 2022 | 5939 | 0.850 |
Why?
|
| Neoplasm Proteins | 7 | 2019 | 652 | 0.840 |
Why?
|
| Sarcoma, Clear Cell | 3 | 2009 | 21 | 0.820 |
Why?
|
| Pathology, Clinical | 1 | 2023 | 20 | 0.800 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2024 | 899 | 0.780 |
Why?
|
| Microscopy, Electron | 1 | 2023 | 307 | 0.770 |
Why?
|
| beta Catenin | 6 | 2016 | 205 | 0.770 |
Why?
|
| Adolescent | 45 | 2024 | 19987 | 0.750 |
Why?
|
| Child, Preschool | 34 | 2025 | 14336 | 0.730 |
Why?
|
| Male | 77 | 2025 | 62489 | 0.700 |
Why?
|
| Liposarcoma, Myxoid | 2 | 2011 | 3 | 0.700 |
Why?
|
| Bone Neoplasms | 7 | 2018 | 428 | 0.690 |
Why?
|
| Genetic Testing | 6 | 2025 | 1056 | 0.680 |
Why?
|
| Female | 80 | 2025 | 68270 | 0.680 |
Why?
|
| Trans-Activators | 4 | 2015 | 675 | 0.680 |
Why?
|
| Neoplasm Transplantation | 4 | 2017 | 361 | 0.680 |
Why?
|
| Repressor Proteins | 6 | 2025 | 761 | 0.670 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2023 | 579 | 0.660 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2025 | 3262 | 0.640 |
Why?
|
| Neovascularization, Pathologic | 3 | 2017 | 233 | 0.640 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2015 | 13 | 0.630 |
Why?
|
| Infant | 31 | 2025 | 12760 | 0.610 |
Why?
|
| Biopsy | 8 | 2021 | 1236 | 0.600 |
Why?
|
| Oncogene Fusion | 4 | 2017 | 24 | 0.600 |
Why?
|
| DNA, Neoplasm | 10 | 2020 | 283 | 0.590 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 138 | 0.580 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2017 | 204 | 0.560 |
Why?
|
| Fibrosarcoma | 3 | 2012 | 24 | 0.560 |
Why?
|
| MAP Kinase Signaling System | 2 | 2019 | 302 | 0.550 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2022 | 167 | 0.550 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2017 | 65 | 0.550 |
Why?
|
| Young Adult | 22 | 2021 | 9655 | 0.540 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2017 | 144 | 0.530 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2017 | 138 | 0.520 |
Why?
|
| Thyroid Neoplasms | 2 | 2020 | 240 | 0.520 |
Why?
|
| Genes, APC | 2 | 2018 | 13 | 0.520 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2019 | 75 | 0.520 |
Why?
|
| Thrombocytosis | 1 | 2017 | 34 | 0.510 |
Why?
|
| Adult | 46 | 2022 | 30377 | 0.510 |
Why?
|
| Phenotype | 5 | 2017 | 4302 | 0.510 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2016 | 93 | 0.500 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 102 | 0.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2021 | 1302 | 0.500 |
Why?
|
| RNA-Binding Protein EWS | 10 | 2014 | 37 | 0.490 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 124 | 0.490 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2016 | 34 | 0.490 |
Why?
|
| Calcium-Binding Proteins | 2 | 2015 | 327 | 0.480 |
Why?
|
| Epithelioid Cells | 3 | 2012 | 12 | 0.480 |
Why?
|
| Liver | 6 | 2023 | 1763 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2014 | 362 | 0.480 |
Why?
|
| Oncogenes | 1 | 2016 | 162 | 0.480 |
Why?
|
| Liver Diseases | 2 | 2019 | 381 | 0.470 |
Why?
|
| Pediatrics | 4 | 2024 | 1198 | 0.470 |
Why?
|
| Thyroid Nodule | 1 | 2015 | 22 | 0.470 |
Why?
|
| RNA-Binding Protein FUS | 2 | 2012 | 18 | 0.460 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2015 | 10 | 0.460 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2015 | 59 | 0.460 |
Why?
|
| Neuroblastoma | 2 | 2017 | 539 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2020 | 1931 | 0.450 |
Why?
|
| Cauda Equina | 1 | 2014 | 7 | 0.450 |
Why?
|
| Carcinogenesis | 2 | 2023 | 344 | 0.450 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2014 | 10 | 0.450 |
Why?
|
| WT1 Proteins | 1 | 2014 | 22 | 0.450 |
Why?
|
| Cyclin B | 1 | 2014 | 22 | 0.440 |
Why?
|
| Glomus Tumor | 1 | 2014 | 14 | 0.440 |
Why?
|
| Prognosis | 13 | 2021 | 4771 | 0.440 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2024 | 1234 | 0.440 |
Why?
|
| Cell Line, Tumor | 8 | 2024 | 3497 | 0.430 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2017 | 222 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2012 | 18 | 0.420 |
Why?
|
| Actins | 1 | 2016 | 311 | 0.420 |
Why?
|
| Sarcoma, Synovial | 4 | 2021 | 22 | 0.420 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2015 | 578 | 0.410 |
Why?
|
| Pathologists | 2 | 2024 | 26 | 0.410 |
Why?
|
| Collagen Type I | 2 | 2012 | 113 | 0.400 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2013 | 67 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2013 | 87 | 0.400 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2022 | 48 | 0.400 |
Why?
|
| DNA-Binding Proteins | 4 | 2011 | 1877 | 0.400 |
Why?
|
| Carcinoma | 1 | 2015 | 279 | 0.400 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2015 | 271 | 0.390 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 3 | 2008 | 14 | 0.390 |
Why?
|
| Hodgkin Disease | 2 | 2015 | 291 | 0.390 |
Why?
|
| Thoracic Neoplasms | 1 | 2012 | 38 | 0.390 |
Why?
|
| Cell Differentiation | 4 | 2021 | 1842 | 0.380 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2024 | 76 | 0.380 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2022 | 148 | 0.380 |
Why?
|
| Myeloproliferative Disorders | 2 | 2013 | 86 | 0.380 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2017 | 552 | 0.380 |
Why?
|
| Thoracic Vertebrae | 1 | 2012 | 66 | 0.380 |
Why?
|
| Isochromosomes | 1 | 2012 | 17 | 0.380 |
Why?
|
| Spinal Neoplasms | 1 | 2012 | 52 | 0.380 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 2 | 2009 | 41 | 0.380 |
Why?
|
| Chromosome Aberrations | 6 | 2020 | 570 | 0.370 |
Why?
|
| Parotid Gland | 1 | 2011 | 17 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2024 | 78 | 0.360 |
Why?
|
| Stem Cells | 1 | 2016 | 683 | 0.360 |
Why?
|
| Vulvar Neoplasms | 2 | 2008 | 21 | 0.350 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2024 | 946 | 0.350 |
Why?
|
| Middle Aged | 34 | 2024 | 27671 | 0.350 |
Why?
|
| Embolization, Therapeutic | 2 | 2025 | 221 | 0.350 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 152 | 0.350 |
Why?
|
| Cell Dedifferentiation | 1 | 2010 | 20 | 0.340 |
Why?
|
| Simian virus 40 | 3 | 2008 | 190 | 0.340 |
Why?
|
| DNA Primers | 2 | 2010 | 602 | 0.330 |
Why?
|
| Liposarcoma | 1 | 2010 | 25 | 0.330 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 105 | 0.330 |
Why?
|
| Chromosome Breakpoints | 1 | 2010 | 81 | 0.330 |
Why?
|
| Stomach Neoplasms | 2 | 2016 | 565 | 0.330 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2010 | 10 | 0.330 |
Why?
|
| Polyomavirus Infections | 2 | 2008 | 87 | 0.330 |
Why?
|
| Tumor Virus Infections | 2 | 2008 | 130 | 0.320 |
Why?
|
| Chimera | 1 | 2010 | 80 | 0.320 |
Why?
|
| Mice | 15 | 2025 | 17594 | 0.320 |
Why?
|
| Neoplasm Invasiveness | 4 | 2017 | 634 | 0.310 |
Why?
|
| DNA Mutational Analysis | 6 | 2015 | 781 | 0.310 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 422 | 0.310 |
Why?
|
| SMARCB1 Protein | 2 | 2020 | 32 | 0.310 |
Why?
|
| Pathology | 1 | 2009 | 27 | 0.310 |
Why?
|
| Treatment Outcome | 13 | 2023 | 12537 | 0.310 |
Why?
|
| Sequence Analysis, RNA | 2 | 2024 | 416 | 0.310 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2011 | 606 | 0.300 |
Why?
|
| CREB-Binding Protein | 1 | 2009 | 55 | 0.300 |
Why?
|
| Antigens, CD34 | 4 | 2012 | 99 | 0.300 |
Why?
|
| Palatine Tonsil | 2 | 2008 | 35 | 0.300 |
Why?
|
| Heterografts | 3 | 2024 | 190 | 0.300 |
Why?
|
| Wnt Proteins | 2 | 2009 | 200 | 0.290 |
Why?
|
| Neoplasm Staging | 6 | 2021 | 1283 | 0.290 |
Why?
|
| Cerebellar Neoplasms | 1 | 2012 | 314 | 0.290 |
Why?
|
| Chondrosarcoma | 1 | 2008 | 13 | 0.290 |
Why?
|
| Genomics | 5 | 2025 | 1545 | 0.290 |
Why?
|
| Pharyngeal Diseases | 1 | 2008 | 17 | 0.290 |
Why?
|
| Medulloblastoma | 1 | 2012 | 378 | 0.280 |
Why?
|
| Aged | 20 | 2018 | 20321 | 0.280 |
Why?
|
| Glioma | 2 | 2022 | 479 | 0.270 |
Why?
|
| Myofibroma | 2 | 2017 | 9 | 0.270 |
Why?
|
| Fasciitis | 2 | 2017 | 18 | 0.260 |
Why?
|
| Infant, Newborn | 12 | 2024 | 8343 | 0.260 |
Why?
|
| Algorithms | 2 | 2022 | 1633 | 0.260 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2019 | 726 | 0.250 |
Why?
|
| Animals | 17 | 2025 | 33043 | 0.250 |
Why?
|
| Liver Transplantation | 4 | 2025 | 1102 | 0.250 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 1221 | 0.250 |
Why?
|
| Real-Time Polymerase Chain Reaction | 4 | 2016 | 523 | 0.250 |
Why?
|
| Sarcoma, Alveolar Soft Part | 3 | 2012 | 9 | 0.250 |
Why?
|
| Immunophenotyping | 3 | 2017 | 330 | 0.240 |
Why?
|
| Sequence Analysis, DNA | 6 | 2022 | 1707 | 0.240 |
Why?
|
| Yttrium Radioisotopes | 2 | 2025 | 27 | 0.240 |
Why?
|
| Intestinal Neoplasms | 1 | 2006 | 36 | 0.240 |
Why?
|
| Tumor Burden | 2 | 2017 | 229 | 0.230 |
Why?
|
| Transaminases | 1 | 2025 | 36 | 0.230 |
Why?
|
| Diagnosis, Differential | 7 | 2024 | 1859 | 0.230 |
Why?
|
| Risk Factors | 9 | 2025 | 10545 | 0.230 |
Why?
|
| Karyotyping | 6 | 2016 | 312 | 0.230 |
Why?
|
| Base Sequence | 9 | 2012 | 2756 | 0.230 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2025 | 28 | 0.230 |
Why?
|
| Fatal Outcome | 5 | 2017 | 358 | 0.230 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 233 | 0.220 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 4 | 2015 | 192 | 0.220 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2025 | 38 | 0.220 |
Why?
|
| Databases, Factual | 3 | 2020 | 1193 | 0.220 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2025 | 50 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 169 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2025 | 57 | 0.220 |
Why?
|
| Molecular Sequence Data | 9 | 2012 | 3584 | 0.220 |
Why?
|
| Glypicans | 1 | 2024 | 40 | 0.220 |
Why?
|
| Germ-Line Mutation | 3 | 2018 | 352 | 0.220 |
Why?
|
| Histiocytes | 2 | 2017 | 18 | 0.220 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2025 | 113 | 0.210 |
Why?
|
| Interleukin-15 | 1 | 2024 | 100 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 22 | 6 | 2013 | 97 | 0.210 |
Why?
|
| Indocyanine Green | 1 | 2024 | 53 | 0.210 |
Why?
|
| Molecular Biology | 2 | 2011 | 68 | 0.210 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 2061 | 0.200 |
Why?
|
| Mice, SCID | 2 | 2017 | 568 | 0.200 |
Why?
|
| Disease Models, Animal | 5 | 2025 | 4426 | 0.200 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 143 | 0.200 |
Why?
|
| Disease-Free Survival | 5 | 2020 | 898 | 0.200 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 19 | 0.190 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 132 | 0.190 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 258 | 0.190 |
Why?
|
| alpha-Fetoproteins | 3 | 2023 | 132 | 0.190 |
Why?
|
| Sclerosis | 2 | 2012 | 29 | 0.190 |
Why?
|
| Rare Diseases | 1 | 2024 | 201 | 0.190 |
Why?
|
| Cytogenetic Analysis | 3 | 2014 | 79 | 0.190 |
Why?
|
| Antigens, Polyomavirus Transforming | 3 | 2008 | 84 | 0.190 |
Why?
|
| Neutrophils | 2 | 2001 | 349 | 0.180 |
Why?
|
| Ki-67 Antigen | 3 | 2024 | 100 | 0.180 |
Why?
|
| Retrospective Studies | 11 | 2023 | 16985 | 0.180 |
Why?
|
| Skull Neoplasms | 1 | 2001 | 14 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 5 | 2020 | 985 | 0.180 |
Why?
|
| Ki-1 Antigen | 1 | 2001 | 30 | 0.180 |
Why?
|
| Lymphatic Metastasis | 3 | 2020 | 424 | 0.170 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2025 | 786 | 0.170 |
Why?
|
| Osteosarcoma | 3 | 2003 | 259 | 0.170 |
Why?
|
| Fixatives | 2 | 2012 | 13 | 0.170 |
Why?
|
| Paraffin Embedding | 2 | 2012 | 39 | 0.170 |
Why?
|
| Formaldehyde | 2 | 2012 | 36 | 0.170 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2022 | 273 | 0.170 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2017 | 63 | 0.160 |
Why?
|
| Hospitals | 1 | 2023 | 428 | 0.160 |
Why?
|
| Carcinoma, Medullary | 1 | 2020 | 15 | 0.160 |
Why?
|
| Bone Marrow | 3 | 2017 | 309 | 0.160 |
Why?
|
| Mitochondria | 1 | 2025 | 729 | 0.160 |
Why?
|
| Hemangioma, Capillary | 1 | 2020 | 17 | 0.160 |
Why?
|
| Cell Cycle Proteins | 3 | 2023 | 677 | 0.160 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 90 | 0.160 |
Why?
|
| Craniocerebral Trauma | 1 | 2001 | 137 | 0.160 |
Why?
|
| Sarcoma, Myeloid | 1 | 2019 | 11 | 0.160 |
Why?
|
| Exome | 1 | 2024 | 1064 | 0.160 |
Why?
|
| Ependymoma | 1 | 2021 | 139 | 0.160 |
Why?
|
| Leukocytosis | 2 | 2017 | 46 | 0.160 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 3901 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 191 | 0.160 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 1004 | 0.150 |
Why?
|
| Proton Therapy | 1 | 2021 | 151 | 0.150 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2019 | 15 | 0.150 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2019 | 11 | 0.150 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 1998 | 45 | 0.150 |
Why?
|
| Tracheal Neoplasms | 1 | 1999 | 20 | 0.150 |
Why?
|
| Azacitidine | 1 | 2019 | 51 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 379 | 0.150 |
Why?
|
| Neuroectodermal Tumors | 1 | 1999 | 12 | 0.150 |
Why?
|
| Lymph Nodes | 3 | 2017 | 373 | 0.150 |
Why?
|
| Hemangioma | 1 | 2020 | 92 | 0.150 |
Why?
|
| Societies, Medical | 1 | 2023 | 738 | 0.150 |
Why?
|
| Discoidin Domain Receptor 2 | 1 | 2018 | 5 | 0.150 |
Why?
|
| Serine Endopeptidases | 2 | 2018 | 191 | 0.150 |
Why?
|
| Adamantinoma | 1 | 2018 | 2 | 0.150 |
Why?
|
| Survival Rate | 4 | 2021 | 2100 | 0.150 |
Why?
|
| Rhabdoid Tumor | 1 | 2019 | 46 | 0.150 |
Why?
|
| Proteostasis | 1 | 2019 | 34 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 39 | 0.140 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 81 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 393 | 0.140 |
Why?
|
| Gene Amplification | 2 | 2013 | 227 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2019 | 122 | 0.140 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2013 | 105 | 0.140 |
Why?
|
| DNA Replication | 1 | 2020 | 347 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 3 | 2017 | 1204 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 169 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 871 | 0.140 |
Why?
|
| Cooperative Behavior | 2 | 2016 | 221 | 0.140 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 90 | 0.140 |
Why?
|
| Chromosome Banding | 1 | 2017 | 136 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 5112 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 3 | 2009 | 360 | 0.130 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 289 | 0.130 |
Why?
|
| Cell Nucleus | 3 | 2012 | 551 | 0.130 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2017 | 30 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 247 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 102 | 0.130 |
Why?
|
| Sarcoma, Small Cell | 1 | 1996 | 1 | 0.130 |
Why?
|
| Cytogenetics | 1 | 1996 | 13 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 42 | 0.130 |
Why?
|
| Monosomy | 1 | 1996 | 25 | 0.130 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 123 | 0.130 |
Why?
|
| Tissue Array Analysis | 4 | 2009 | 135 | 0.130 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 44 | 0.120 |
Why?
|
| Chromosome Mapping | 3 | 2023 | 1054 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2024 | 4953 | 0.120 |
Why?
|
| Receptors, Purinergic P2X3 | 1 | 2015 | 3 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1705 | 0.120 |
Why?
|
| Transcriptional Regulator ERG | 2 | 2013 | 39 | 0.120 |
Why?
|
| Nose Neoplasms | 1 | 1996 | 30 | 0.120 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2016 | 101 | 0.120 |
Why?
|
| Transplantation Conditioning | 1 | 2017 | 304 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 436 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 198 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2015 | 38 | 0.120 |
Why?
|
| Autophagy | 1 | 2019 | 404 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 203 | 0.120 |
Why?
|
| Ikaros Transcription Factor | 1 | 2015 | 29 | 0.120 |
Why?
|
| Integrases | 1 | 2016 | 153 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 4 | 2022 | 613 | 0.120 |
Why?
|
| Mutagenesis | 1 | 2016 | 332 | 0.120 |
Why?
|
| Ifosfamide | 1 | 2015 | 30 | 0.110 |
Why?
|
| Vinblastine | 1 | 2015 | 55 | 0.110 |
Why?
|
| International Cooperation | 1 | 2015 | 157 | 0.110 |
Why?
|
| Recombination, Genetic | 1 | 2016 | 418 | 0.110 |
Why?
|
| Bortezomib | 1 | 2015 | 70 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2015 | 47 | 0.110 |
Why?
|
| Mitotic Index | 1 | 2014 | 17 | 0.110 |
Why?
|
| Telomerase | 1 | 2015 | 153 | 0.110 |
Why?
|
| Pyrazines | 1 | 2015 | 77 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 329 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2012 | 60 | 0.110 |
Why?
|
| Risk | 1 | 2016 | 729 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2015 | 576 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 443 | 0.110 |
Why?
|
| Mice, Knockout | 3 | 2019 | 3709 | 0.110 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2014 | 22 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 686 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 5 | 2008 | 1479 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2014 | 106 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2019 | 516 | 0.100 |
Why?
|
| Muir-Torre Syndrome | 1 | 2013 | 1 | 0.100 |
Why?
|
| Time Factors | 5 | 2021 | 6124 | 0.100 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2013 | 36 | 0.100 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2005 | 27 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 424 | 0.100 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2013 | 31 | 0.100 |
Why?
|
| Lipoma | 1 | 2013 | 24 | 0.100 |
Why?
|
| Cells, Cultured | 3 | 2017 | 2893 | 0.100 |
Why?
|
| Chromosomal Instability | 1 | 2013 | 58 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 1224 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 2015 | 420 | 0.100 |
Why?
|
| Fibroma | 1 | 2013 | 29 | 0.100 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 32 | 0.100 |
Why?
|
| Cell Lineage | 1 | 2014 | 321 | 0.100 |
Why?
|
| Mucin-4 | 1 | 2012 | 11 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2014 | 354 | 0.100 |
Why?
|
| Exons | 2 | 2012 | 757 | 0.100 |
Why?
|
| Microsatellite Repeats | 1 | 2013 | 229 | 0.090 |
Why?
|
| Forkhead Box Protein O1 | 2 | 2009 | 100 | 0.090 |
Why?
|
| Age Factors | 2 | 2015 | 2788 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 1999 | 973 | 0.090 |
Why?
|
| Atrophy | 1 | 2012 | 237 | 0.090 |
Why?
|
| Mass Screening | 1 | 2018 | 802 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 90 | 0.090 |
Why?
|
| Patched Receptors | 1 | 2011 | 27 | 0.090 |
Why?
|
| Tissue Fixation | 1 | 2012 | 36 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 3693 | 0.090 |
Why?
|
| Patched-1 Receptor | 1 | 2011 | 38 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 80 | 0.090 |
Why?
|
| Alleles | 1 | 2016 | 1609 | 0.090 |
Why?
|
| Cross Reactions | 1 | 2012 | 180 | 0.090 |
Why?
|
| Fibromatosis, Abdominal | 1 | 2011 | 1 | 0.090 |
Why?
|
| Hepatectomy | 2 | 2023 | 119 | 0.090 |
Why?
|
| Primary Myelofibrosis | 1 | 2012 | 51 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 1168 | 0.090 |
Why?
|
| Rabbits | 1 | 2012 | 614 | 0.090 |
Why?
|
| Models, Biological | 1 | 2016 | 1370 | 0.090 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 3 | 2008 | 13 | 0.090 |
Why?
|
| Mouth Neoplasms | 1 | 2012 | 93 | 0.090 |
Why?
|
| Cysts | 1 | 2012 | 89 | 0.090 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2011 | 104 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2015 | 933 | 0.090 |
Why?
|
| Europe | 1 | 2012 | 358 | 0.090 |
Why?
|
| Nuclear Envelope | 1 | 2011 | 19 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2011 | 29 | 0.090 |
Why?
|
| Enzyme Induction | 1 | 2010 | 97 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2019 | 4472 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1493 | 0.080 |
Why?
|
| Myofibroblasts | 1 | 2011 | 59 | 0.080 |
Why?
|
| Neoplasm, Residual | 2 | 2009 | 131 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 80 | 0.080 |
Why?
|
| Transcriptome | 1 | 2016 | 1051 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2225 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 220 | 0.080 |
Why?
|
| Recurrence | 3 | 2025 | 1406 | 0.080 |
Why?
|
| Transcription Factor HES-1 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2009 | 27 | 0.070 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2009 | 38 | 0.070 |
Why?
|
| Myogenin | 1 | 2008 | 9 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2969 | 0.070 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2008 | 5 | 0.070 |
Why?
|
| Glycogen | 1 | 2008 | 50 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2020 | 708 | 0.070 |
Why?
|
| Immunocompetence | 1 | 2008 | 30 | 0.070 |
Why?
|
| Piperazines | 1 | 2010 | 255 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 193 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2010 | 380 | 0.070 |
Why?
|
| Extremities | 1 | 2008 | 74 | 0.070 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2008 | 52 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2008 | 109 | 0.070 |
Why?
|
| Remission Induction | 2 | 2019 | 298 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2020 | 1569 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2005 | 152 | 0.070 |
Why?
|
| Histological Techniques | 1 | 2007 | 19 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2009 | 285 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 286 | 0.070 |
Why?
|
| Skin | 1 | 2010 | 516 | 0.070 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 1758 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2009 | 331 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2010 | 405 | 0.060 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 103 | 0.060 |
Why?
|
| Syndrome | 1 | 2009 | 1135 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2013 | 1025 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 2 | 1998 | 217 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 988 | 0.060 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2006 | 11 | 0.060 |
Why?
|
| Disease Progression | 3 | 2021 | 2109 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2016 | 1495 | 0.060 |
Why?
|
| Poliovirus Vaccine, Inactivated | 1 | 2005 | 12 | 0.060 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2006 | 29 | 0.060 |
Why?
|
| Genotype | 1 | 2012 | 2593 | 0.060 |
Why?
|
| Hashimoto Disease | 1 | 2006 | 27 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2009 | 538 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 517 | 0.060 |
Why?
|
| Ribonucleoproteins | 2 | 1996 | 57 | 0.060 |
Why?
|
| Nuclear Proteins | 3 | 2018 | 1204 | 0.060 |
Why?
|
| Receptors, Purinergic P2Y | 1 | 2025 | 6 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 21 | 2 | 1996 | 26 | 0.060 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2025 | 72 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2011 | 6663 | 0.060 |
Why?
|
| Age of Onset | 2 | 2020 | 609 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2020 | 2397 | 0.060 |
Why?
|
| Receptors, Cytokine | 1 | 2025 | 65 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2882 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2021 | 6200 | 0.060 |
Why?
|
| Apoptosis | 2 | 2022 | 1811 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2024 | 13 | 0.050 |
Why?
|
| Melanoma | 2 | 2006 | 898 | 0.050 |
Why?
|
| Cost Savings | 1 | 2024 | 78 | 0.050 |
Why?
|
| Lymphoma | 2 | 2005 | 319 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2024 | 63 | 0.050 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2003 | 6 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2024 | 68 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 2581 | 0.050 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 1 | 2003 | 7 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2025 | 231 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2021 | 3583 | 0.050 |
Why?
|
| Myxoma | 1 | 2003 | 29 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 96 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 247 | 0.050 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2006 | 138 | 0.050 |
Why?
|
| Inflammation | 1 | 2011 | 1420 | 0.050 |
Why?
|
| Carcinogens | 1 | 2023 | 128 | 0.050 |
Why?
|
| Prevalence | 1 | 2010 | 2591 | 0.050 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2003 | 75 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 56 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2006 | 515 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 406 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2003 | 152 | 0.050 |
Why?
|
| Historiography | 1 | 2002 | 2 | 0.050 |
Why?
|
| State Medicine | 1 | 2002 | 22 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 108 | 0.050 |
Why?
|
| E2F6 Transcription Factor | 1 | 2001 | 1 | 0.040 |
Why?
|
| Activin Receptors | 1 | 2001 | 14 | 0.040 |
Why?
|
| Fourth Ventricle | 1 | 2021 | 9 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 133 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 125 | 0.040 |
Why?
|
| Cell Line | 2 | 2016 | 2560 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2008 | 1048 | 0.040 |
Why?
|
| Biomarkers | 1 | 2010 | 3217 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 477 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2022 | 146 | 0.040 |
Why?
|
| Brain Stem | 1 | 2021 | 109 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2015 | 585 | 0.040 |
Why?
|
| Inpatients | 1 | 2024 | 541 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2003 | 441 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2020 | 46 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2024 | 775 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 2 | 2003 | 1098 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 1997 | 251 | 0.040 |
Why?
|
| Frozen Sections | 1 | 1999 | 26 | 0.040 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 2 | 1996 | 23 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2019 | 57 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 61 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2019 | 97 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 3 | 1996 | 678 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2018 | 42 | 0.040 |
Why?
|
| Granulosa Cell Tumor | 1 | 2018 | 38 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 110 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 750 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 122 | 0.040 |
Why?
|
| Proto-Oncogenes | 1 | 1997 | 36 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 1997 | 21 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2018 | 139 | 0.030 |
Why?
|
| Tissue Donors | 2 | 1998 | 486 | 0.030 |
Why?
|
| Gene Expression | 2 | 2005 | 1482 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2018 | 229 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1997 | 213 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2017 | 83 | 0.030 |
Why?
|
| Molecular Motor Proteins | 1 | 2016 | 28 | 0.030 |
Why?
|
| International Agencies | 1 | 2016 | 29 | 0.030 |
Why?
|
| Myosin Heavy Chains | 1 | 2016 | 74 | 0.030 |
Why?
|
| United States | 1 | 2012 | 11297 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 172 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 690 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 642 | 0.030 |
Why?
|
| Germinal Center | 2 | 2006 | 36 | 0.030 |
Why?
|
| Ovary | 1 | 2018 | 358 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2002 | 665 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 230 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1998 | 572 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 1996 | 76 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2009 | 824 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 198 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2016 | 344 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2008 | 1363 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 253 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 266 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 658 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2014 | 114 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2005 | 448 | 0.030 |
Why?
|
| Los Angeles | 1 | 2013 | 16 | 0.030 |
Why?
|
| Immediate-Early Proteins | 1 | 1994 | 57 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2014 | 67 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 1014 | 0.030 |
Why?
|
| Axilla | 1 | 2013 | 39 | 0.030 |
Why?
|
| Neurons | 1 | 2003 | 1919 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 39 | 0.030 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2013 | 52 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2013 | 41 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 510 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2014 | 143 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2007 | 2537 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 1753 | 0.020 |
Why?
|
| Incidence | 1 | 2020 | 3247 | 0.020 |
Why?
|
| Anemia, Myelophthisic | 1 | 2012 | 2 | 0.020 |
Why?
|
| Reticulin | 1 | 2012 | 7 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2012 | 14 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 999 | 0.020 |
Why?
|
| Clone Cells | 2 | 2006 | 163 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2012 | 64 | 0.020 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2011 | 4 | 0.020 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2012 | 31 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2012 | 31 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 774 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2015 | 380 | 0.020 |
Why?
|
| Adenosine Deaminase | 1 | 2011 | 90 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2012 | 168 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2013 | 415 | 0.020 |
Why?
|
| Eosinophilia | 1 | 2012 | 103 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2012 | 135 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 290 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2010 | 16 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 47 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2013 | 475 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 79 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 235 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4502 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 120 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2011 | 223 | 0.020 |
Why?
|
| PAX7 Transcription Factor | 1 | 2008 | 20 | 0.020 |
Why?
|
| MyoD Protein | 1 | 2008 | 22 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2008 | 64 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2005 | 3311 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 730 | 0.020 |
Why?
|
| Vulva | 1 | 2008 | 14 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 708 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 398 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 891 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2009 | 195 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 82 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 759 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 1995 | 2304 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2007 | 111 | 0.020 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2006 | 4 | 0.020 |
Why?
|
| Pseudolymphoma | 1 | 2005 | 4 | 0.020 |
Why?
|
| Neprilysin | 1 | 2006 | 19 | 0.020 |
Why?
|
| Costa Rica | 1 | 2005 | 15 | 0.020 |
Why?
|
| Drug Contamination | 1 | 2005 | 34 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 2005 | 28 | 0.010 |
Why?
|
| Genes, Viral | 1 | 2005 | 156 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 2006 | 99 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 2012 | 3063 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 138 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2006 | 754 | 0.010 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2003 | 9 | 0.010 |
Why?
|
| Receptors, Lipoprotein | 1 | 2003 | 10 | 0.010 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2003 | 74 | 0.010 |
Why?
|
| Trisomy | 1 | 2003 | 107 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2003 | 297 | 0.010 |
Why?
|
| Receptors, LDL | 1 | 2003 | 106 | 0.010 |
Why?
|
| History, 16th Century | 1 | 2002 | 27 | 0.010 |
Why?
|
| History, 17th Century | 1 | 2002 | 35 | 0.010 |
Why?
|
| Spain | 1 | 2002 | 60 | 0.010 |
Why?
|
| HIV-1 | 1 | 2005 | 469 | 0.010 |
Why?
|
| History, 18th Century | 1 | 2002 | 69 | 0.010 |
Why?
|
| Comorbidity | 1 | 2005 | 1559 | 0.010 |
Why?
|
| Scalp | 1 | 2000 | 57 | 0.010 |
Why?
|
| Prednisone | 1 | 2000 | 240 | 0.010 |
Why?
|
| Vincristine | 1 | 2000 | 190 | 0.010 |
Why?
|
| Transcription, Genetic | 2 | 1995 | 1377 | 0.010 |
Why?
|
| Fetus | 1 | 2003 | 578 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2000 | 286 | 0.010 |
Why?
|
| Y Chromosome | 1 | 1998 | 45 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 421 | 0.010 |
Why?
|
| Viral Matrix Proteins | 1 | 1998 | 107 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1998 | 28 | 0.010 |
Why?
|
| Forearm | 1 | 1998 | 38 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 69 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1998 | 235 | 0.010 |
Why?
|
| Sex Chromosomes | 1 | 1997 | 30 | 0.010 |
Why?
|
| X Chromosome | 1 | 1998 | 327 | 0.010 |
Why?
|
| Liver Failure | 1 | 1997 | 89 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 449 | 0.010 |
Why?
|
| Kidney | 1 | 2003 | 1283 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1998 | 510 | 0.010 |
Why?
|
| Activating Transcription Factor 1 | 1 | 1995 | 4 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1997 | 639 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1997 | 986 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1995 | 121 | 0.010 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1994 | 10 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1994 | 136 | 0.010 |
Why?
|
| Reoperation | 1 | 1997 | 818 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1995 | 822 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 1994 | 38 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1995 | 315 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1994 | 784 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 1293 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 2541 | 0.000 |
Why?
|
| HIV Infections | 1 | 2000 | 1951 | 0.000 |
Why?
|